SCHEMBL2039704

SCHEMBL2039704

Cc1cc(NCc2cc(F)ccc2O)cc(Br)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.43
MEN1 O00255 5/20 0.43
APP P05067 2/20 0.41
PDE2A O00408 1/20 0.41
MAPT P10636 5/20 0.40
ALDH1A1 P00352 3/20 0.40
EGFR P00533 1/20 0.40
POLB P06746 1/20 0.40
PLEC Q15149 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
P2RX1 P51575 1/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
KDM4E B2RXH2 2/20 0.37
HPGD P15428 2/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37
ALPL P05186 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2038643 0.91 MAP2K4 (0.43) KMT2AMEN1PDE2AMAPTALDH1A1
SCHEMBL2042919 0.85 MEN1 (0.41) KMT2AMEN1APPPDE2AMAPT
SCHEMBL2044460 0.82 MAPT (0.55) KMT2AMEN1APPMAPTALDH1A1
SCHEMBL2038199 0.78 KDM4E (0.46) KMT2AMEN1APPMAPTALDH1A1
SCHEMBL2038649 0.75 MAP2K4 (0.41) KMT2AMEN1MAPTALDH1A1POLB
SCHEMBL2042920 0.73 GAA (0.40) KMT2AMEN1APPMAPTALDH1A1
SCHEMBL2038957 0.73 MEN1 (0.42) KMT2AMEN1APPPDE2AMAPT
SCHEMBL2042255 0.73 NPSR1 (0.50) KMT2AMEN1APPMAPTALDH1A1
SCHEMBL2048102 0.73 KMT2A (0.50) KMT2AMEN1APPMAPTALDH1A1
SCHEMBL20376006 0.72 MAOB (0.56) KMT2AMEN1APPMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10202346-B2 Phenol derivatives and the pharmaceutical or cosmetic use thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2019-02-12 US claimed
US-20130178633-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-07-11 US claimed
US-10202346-B2 Phenol derivatives and the pharmaceutical or cosmetic use thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2019-02-12 US disclosed
EP-2516400-B1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RES & DEV (FR) 2017-03-22 EP disclosed
US-20160068488-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF COLLETTE PATRICE LUCIEN MAURICE (FR) 2016-03-10 US disclosed
US-20130178633-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-07-11 US disclosed
EP-2516400-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF Galderma Research & Development (FR) 2012-10-31 EP disclosed
WO-2011077046-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068488-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF TYR, MITF, CUTA KMT2A 2277/4885MEN1 3059/4885APP 3234/4885
US-20130178633-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF TYR, MITF, CUTA KMT2A 2277/4885MEN1 3059/4885APP 3234/4885
US-10202346-B2 Phenol derivatives and the pharmaceutical or cosmetic use thereof TYR, MITF, CUTA KMT2A 2277/4885MEN1 3059/4885APP 3234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.